Mogamulizumab Offers Option for Rare Relapsed, Refractory T-Cell Leukemia/Lymphoma
The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.
Early TKI Responses Predict CML Survival, Especially With Dasatinib
Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.
Alternate CTL019 Dosing Schedule Reduced Toxicity in Adult ALL
New research has shown that a higher dose of CTL019 with split dosing was associated with reduced toxicity in adult patients with relapsed, refractory CD19-positive ALL.
Novel Agent Active in FLT3-Positive Acute Myeloid Leukemia
Crenolanib, a type I pan FLT3 inhibitor, had activity in a group of patients with FLT3-positive acute myeloid leukemia (AML), including a number of patients with FLT3 D835 mutations.
Bortezomib Boosts Complete Remissions in High-Risk Follicular Lymphoma
Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.
Evolving M-Protein, Hemoglobin Identified Ultra-High-Risk Smoldering Myeloma
Researchers were able to identify a subset of patients with smoldering multiple myeloma who have a greater than 80% risk of progressing to myeloma within 2 years.
Isatuximab Active in Heavily Pretreated Relapsed, Refractory Myeloma
Monotherapy with the monoclonal antibody isatuximab was effective and well-tolerated in a small study of patients with relapsed and refractory multiple myeloma.
By clicking Accept, you agree to become a member of the UBM Medica Community.